Evidence map›Paper›PMID 37237453›Full record

ArticleBiology2023

Josiah E Hardesty, Jeffrey B Warner, Ying L Song, Alison Floyd, Craig J McClain, Dennis R Warner, Irina A Kirpich

Open access · goldAbstract read
In one paragraph

Article in Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Bacterial and host interactions inFrontiers in microbiology · 2025
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Josiah E HardestyDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Jeffrey B WarnerDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Ying L SongDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Alison FloydDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Craig J McClainDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.ORCID 0000-0002-7219-8939
Dennis R WarnerDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Irina A KirpichDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
University of Louisville · US

Funding

Role of oxidized linoleic acid metabolites in the pathogenesis of alcoholic liver diseaseP20GM113226 · NIGMS · UNIVERSITY OF LOUISVILLE · PI ZHANG, XIANG · 2016 to 2025
$24.1M
The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ InjuryP50AA024337 · NIAAA · UNIVERSITY OF LOUISVILLE · PI SHIRISH S BARVE · 2016 to 2026
$17.9M
University of Louisville Center for Integrative Environmental Health SciencesP30ES030283 · NIEHS · UNIVERSITY OF LOUISVILLE · PI J CHRISTOPHER STATES · 2020 to 2026
$10.0M
Integrated therapies for alcohol use and ALD (ITAALD) Network -UofL Clinical CenterU01AA026980 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN, Ashwani K Singal · 2018 to 2026
$2.9M
Role of Soluble Epoxide Hydrolase in Alcohol-Associated Liver DiseaseR01AA028905 · NIAAA · UNIVERSITY OF LOUISVILLE · PI Irina A. Kirpich · 2022 to 2026
$2.1M
Mechanisms for alcohol induced gut barrier dysfunction in ALDR01AA023681 · NIAAA · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2014 to 2018
$1.6M
Pilot Trial UO1 DUR-928U01AA026934 · NIAAA · UNIVERSITY OF LOUISVILLE · PI MCCLAIN, CRAIG J. · 2018 to 2022
$356k
Restoration and preservation of hepatic cardiolipin levels promotes liver regeneration in AHK99AA030627 · NIAAA · UNIVERSITY OF LOUISVILLE · PI HARDESTY, JOSIAH E · 2022 to 2023
$269k
RvD1-FPR2 signaling ameliorates alcoholic liver diseaseF32AA027950 · NIAAA · UNIVERSITY OF LOUISVILLE · PI HARDESTY, JOSIAH E · 2020 to 2022
$164k
sEH Inhibition in Alcoholic Liver Disease: A Novel Therapeutic StrategyF31AA028423 · NIAAA · UNIVERSITY OF LOUISVILLE · PI WARNER, JEFFREY B · 2020 to 2022
$92k
NIAAA NIH HHS F31AA028423NIAAA NIH HHS F32 AA027950NIAAA NIH HHS F32AA027950NIAAA NIH HHS K99 AA030627NIAAA NIH HHS K99AA030627NIAAA NIH HHS L70 AA027913NIAAA NIH HHS P50 AA024337NIAAA NIH HHS P50AA024337NIAAA NIH HHS R01AA023681NIAAA NIH HHS R01AA028905NIAAA NIH HHS U01AA026926NIAAA NIH HHS U01AA026934NIAAA NIH HHS U01AA026980NIEHS NIH HHS P30 ES030283NIGMS NIH HHS P20 GM113226NIGMS NIH HHS P20GM113226
6 · The paper itself

Abstract

Alcohol-associated liver disease (ALD) is the most common chronic liver disease and carries a significant healthcare burden. ALD has no long-term treatment options aside from abstinence, and the mechanisms that contribute to its pathogenesis are not fully understood. This study aimed to investigate the role of formyl peptide receptor 2 (FPR2), a receptor for immunomodulatory signals, in the pathogenesis of ALD. WT and

Indexed as

alcohol-associated liver diseaseFPR2restorative MoMFs

Identifiers

PMID37237453
PMCPMC10215685
OpenAlexW4366834081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.